Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

45 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Heregulin-1ß and HER3 in hepatocellular carcinoma: status and regulation by insulin.
Buta C, Benabou E, Lequoy M, Régnault H, Wendum D, Meratbene F, Chettouh H, Aoudjehane L, Conti F, Chrétien Y, Scatton O, Rosmorduc O, Praz F, Fartoux L, Desbois-Mouthon C. Buta C, et al. Among authors: regnault h. J Exp Clin Cancer Res. 2016 Aug 11;35(1):126. doi: 10.1186/s13046-016-0402-3. J Exp Clin Cancer Res. 2016. PMID: 27514687 Free PMC article.
Erratum to: Heregulin-1ß and HER3 in hepatocellular carcinoma: status and regulation by insulin.
Buta C, Benabou E, Lequoy M, Régnault H, Wendum D, Merabtene F, Chettouh H, Aoudjehane L, Conti F, Chrétien Y, Scatton O, Rosmorduc O, Praz F, Fartoux L, Desbois-Mouthon C. Buta C, et al. Among authors: regnault h. J Exp Clin Cancer Res. 2016 Sep 28;35(1):154. doi: 10.1186/s13046-016-0438-4. J Exp Clin Cancer Res. 2016. PMID: 27680564 Free PMC article. No abstract available.
ESM1 as a Marker of Macrotrabecular-Massive Hepatocellular Carcinoma.
Calderaro J, Meunier L, Nguyen CT, Boubaya M, Caruso S, Luciani A, Amaddeo G, Regnault H, Nault JC, Cohen J, Oberti F, Michalak S, Bouattour M, Vilgrain V, Pageaux GP, Ramos J, Barget N, Guiu B, Paradis V, Aubé C, Laurent A, Pawlotsky JM, Ganne-Carrié N, Zucman-Rossi J, Seror O, Ziol M. Calderaro J, et al. Among authors: regnault h. Clin Cancer Res. 2019 Oct 1;25(19):5859-5865. doi: 10.1158/1078-0432.CCR-19-0859. Epub 2019 Jul 29. Clin Cancer Res. 2019. PMID: 31358545
Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area.
Amaddeo G, Brustia R, Allaire M, Lequoy M, Hollande C, Regnault H, Blaise L, Ganne-Carrié N, Séror O, Larrey E, Lim C, Scatton O, El Mouhadi S, Ozenne V, Paye F, Balladur P, Dohan A, Massault PP, Pol S, Dioguardi Burgio M, Vilgrain V, Sepulveda A, Cauchy F, Luciani A, Sommacale D, Leroy V, Roudot-Thoraval F, Bouattour M, Nault JC; Paris Liver Cancer Group. Amaddeo G, et al. Among authors: regnault h. JHEP Rep. 2021 Feb;3(1):100199. doi: 10.1016/j.jhepr.2020.100199. Epub 2020 Dec 22. JHEP Rep. 2021. PMID: 33163949 Free PMC article.
Immune Profiling of Combined Hepatocellular- Cholangiocarcinoma Reveals Distinct Subtypes and Activation of Gene Signatures Predictive of Response to Immunotherapy.
Nguyen CT, Caruso S, Maille P, Beaufrère A, Augustin J, Favre L, Pujals A, Boulagnon-Rombi C, Rhaiem R, Amaddeo G, di Tommaso L, Luciani A, Regnault H, Brustia R, Scatton O, Charlotte F, Brochériou I, Sommacale D, Soussan P, Leroy V, Laurent A, Le VK, Ta VT, Trinh HS, Tran TL, Gentien D, Rapinat A, Nault JC, Allaire M, Mulé S, Zucman-Rossi J, Pawlotsky JM, Tournigand C, Lafdil F, Paradis V, Calderaro J. Nguyen CT, et al. Among authors: regnault h. Clin Cancer Res. 2022 Feb 1;28(3):540-551. doi: 10.1158/1078-0432.CCR-21-1219. Epub 2021 Nov 16. Clin Cancer Res. 2022. PMID: 34785581
Nestin as a diagnostic and prognostic marker for combined hepatocellular-cholangiocarcinoma.
Calderaro J, Di Tommaso L, Maillé P, Beaufrère A, Nguyen CT, Heij L, Gnemmi V, Graham RP, Charlotte F, Chartier S, Wendum D, Vij M, Allende D, Diaz A, Fuster C, Rivière B, Herrero A, Augustin J, Evert K, Calvisi DF, Leow WQ, Leung HHW, Bednarsch J, Boleslawski E, Rela M, Chan AW, Forner A, Reig M, Pujals A, Favre L, Allaire M, Scatton O, Uguen A, Trépo E, Sanchez LO, Chatelain D, Remmelink M, Boulagnon-Rombi C, Bazille C, Sturm N, Menahem B, Frouin E, Tougeron D, Tournigand C, Kempf E, Kim H, Ningarhari M, Michalak-Provost S, Kather JN, Gouw ASH, Gopal P, Brustia R, Vibert E, Schulze K, Rüther DF, Weidemann SA, Rhaiem R, Nault JC, Laurent A, Amaddeo G, Regnault H, de Martin E, Sempoux C, Navale P, Shinde J, Bacchuwar K, Westerhoff M, Lo RC, Sebbagh M, Guettier C, Lequoy M, Komuta M, Ziol M, Paradis V, Shen J, Caruso S. Calderaro J, et al. Among authors: regnault h. J Hepatol. 2022 Dec;77(6):1586-1597. doi: 10.1016/j.jhep.2022.07.019. Epub 2022 Aug 18. J Hepatol. 2022. PMID: 35987274
Systemic Treatments with Tyrosine Kinase Inhibitor and Platinum-Based Chemotherapy in Patients with Unresectable or Metastatic Hepatocholangiocarcinoma.
Gigante E, Hobeika C, Le Bail B, Paradis V, Tougeron D, Lequoy M, Bouattour M, Blanc JF, Ganne-Carrié N, Tran H, Hollande C, Allaire M, Amaddeo G, Regnault H, Vigneron P, Ronot M, Elkrief L, Verset G, Trepo E, Zaanan A, Ziol M, Ningarhari M, Calderaro J, Edeline J, Nault JC. Gigante E, et al. Among authors: regnault h. Liver Cancer. 2022 Jun 14;11(5):460-473. doi: 10.1159/000525488. eCollection 2022 Sep. Liver Cancer. 2022. PMID: 36158591 Free PMC article.
Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area: What's new 12 months later?
Brustia R, Bouattour M, Allaire M, Lequoy M, Hollande C, Regnault H, Blaise L, Ganne-Carrié N, Vilgrain V, Larrey E, Lim C, Scatton O, Mouhadi SE, Ozenne V, Paye F, Balladur P, Dohan A, Massault PP, Pol S, Dioguardi Burgio M, Sepulveda A, Cauchy F, Luciani A, Sommacale D, Leroy V, Calderaro J, Roudot-Thoraval F, Nault JC, Amaddeo G; “Paris Liver Cancer Group”. Brustia R, et al. Among authors: regnault h. Ann Hepatol. 2023 Nov-Dec;28(6):101141. doi: 10.1016/j.aohep.2023.101141. Epub 2023 Jul 17. Ann Hepatol. 2023. PMID: 37468096 Free article.
Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO - PRODIGE 82).
Vienot A, Jacquin M, Rebucci-Peixoto M, Pureur D, Ghiringhelli F, Assenat E, Hammel P, Rosmorduc O, Stouvenot M, Allaire M, Bouattour M, Regnault H, Fratte S, Raymond E, Soularue E, Husson-Wetzel S, Di Martino V, Muller A, Clairet AL, Fagnoni-Legat C, Adotevi O, Meurisse A, Vernerey D, Borg C. Vienot A, et al. Among authors: regnault h. BMC Cancer. 2023 Jul 29;23(1):710. doi: 10.1186/s12885-023-11065-0. BMC Cancer. 2023. PMID: 37516867 Free PMC article. Clinical Trial.
45 results